Organoid Cultures Derived from Patients with Advanced Prostate Cancer
A
PTEN expression
TP53 expression
C

D

Figure5.LossofTumorSuppressorsPTEN,TP53,RB1,andCDKN2AinProstateOrganoidLines
(A)OncoprintviewofPTEN,TP53,RB1,andCDKN2A.The lloftherectangledenotescopynumberchange(homozygousdeletiondarkblue,heterozygousdeletionlightblue,GAIN:red).Theborderoftherectangledenotesgeneexpres-sionchange.Greensquaredenotesmutation.(B)WesternblotofPTEN,RB,phosphorylatedRB(S807/S811),p16,andGAPDHofnormalprostateorganoidsandprostatecancerorganoidlines.(C–E)GeneexpressionofPTEN,TP53,andRB1innormalprostatetissue,primarycancer,andCRPCfromtheMichigandataset.ForCRPC,copynumberandmutationaldataareavailableformostsamples.Opencirclesindicatesthatmutational/copynumberdataarenotavailable.Green llin-dicatesmutation.Lightanddarkblue llindicatesheterozygousandhomozygousloss.
(F)ScatterplotofgeneexpressionofRB1andCDKN2Ainbenign(orangetriangle),primarycancer(pinksquare),andCRPC(blackcircles).SeealsoFigureS5forRNA-seqandArray-CGHtracksofCDKN2A.
RB1 expression
B
RB1 expression
E

F


CDKN2A expression
PriorstudieshavedocumentedheterozygouslossRB1inprostatecancer,suggestinghaploinsuf ciencyissuf cienttopromotetumorigenesis(Sharmaetal.,2010).Ofnote,threeor-ganoidlineshadheterozygousRB1loss(MSK-PCa1,MSK-PCa4,andMSK-PCa5)buthadnodetectableRB1transcriptorRBproteinexpression(Figures5Aand5B).RNA-seqanalysisrevealedcompleteRB1deletioninMSK-PCa5thatwasmissedonarray-CGHandWES(FigureS1C),possiblyexplainedbycopy-neutralgenomicrearrangementoftheremainingallele.ToexplorewhethercompletelossofRB1maybemorecommoninprostatecancerthanpreviouslyappreciated,weexaminedtheRB1genelocusandmRNAlevelsinaclinicalCRPCdataset(Grassoetal.,2012)andfoundhomozygouslossandreducedexpressionin 70%ofcases(Figure5E).Interestingly,twolineswithoutRB1alterations(MSK-PCa3andMSK-PCa6)havebial-leliclossofthetumorsuppressorlocusCDKN2A(FiguresS5AandS5B),providinganothermechanismtodisableRBpathwayfunction.ConsistentwithCDKN2Ageneloss,thesetwolineshavehyperphosphorylatedRBasaconsequenceofunre-strainedCDK4/6kinaseactivityduetolossofp16.CDKN2AdeletionisseenrarelyinclinicalCRPCsamplesamongtheRBintactsubset(3/67totalsamples,4.5%).Rather,mostCRPCtumorsexhibitCDKN2Aoverexpression,likelyduep53/RBloss(Figure5F).Indeed,theorganoidlineswithRBproteinlossandP53mutationhadincreasedp16expression(Figure5B).Patient-DerivedOrganoidLinesasGeneticallyManipulatableModelsforDrugResponse
ToexplorethesuitabilityofCRPC-derivedorganoidlinesfordrugtesting,weperformedgrowthassaystodeterminesensi-tivitytoenzalutamideaswellastotwoPI3-kinasepathwayinhib-itors,everolimusandBKM-120,thatarecurrentlyinclinicaltrialsforCRPC(Figures6A–6C).TheAR-ampli edMSK-PCa2linewasexquisitelysensitivetoenzalutamidewithanIC-50ofapproximately50nM,whereastheotherlineswereresistant.
8Cell159,1–12,September25,2014ª2014ElsevierInc.
TheMSK-PCa2organoidline,whichharborsbothPTENlossandPIK3R1mutation,wassensitivetobotheverolimusandBKM-120.Theseorganoidmodelsarealsoamenabletoinvivostudiesusingbioluminescencetotracktumorresponse.Asexpected,AR-ampli edMSK-PCa2-derivedxenograftswerehighlysensitivetoenzalutamide,recapitulatingtheinvitroresult(Figures6Dand6E),whereasARnegativeMSK-PCa1xeno-graftswereresistant.ForbothMSK-PCa1andMSK-PCa2,ever-olimussigni cantlyslowedtumorgrowthratebutdidnotinduceshrinkage.Furthermore,everolimussigni cantlyincreasedthetumorresponsetoenzalutamideinMSK-PCa2.DISCUSSION
Thepastfewyearshaveseenadramaticincreaseinthenum-berofapprovedtherapies,withseveralpromisinginvestiga-tionalagentsinlatestagedevelopmenttotreatCRPC.Theseincludethenext-generationantiandrogenenzalutamideandtheandrogensynthesisinhibitorabirateroneacetate,bothofwhichhavebeenshowntosigni cantlyprolonglife(deBonoetal.,2011;Ryanetal.,2012;Scheretal.,2012).Theresponse,however,ishighlyvariableandonly 30%attaindurableresponseof>6months(RathkopfandScher,2013).Thus,bothanimprovedunderstandingofthemoleculardeterminantsofresistancetotheseagentsaswellasdevelopmentofnovelther-apeuticsareneeded.Progresshasbeenhamperedbythelackofinvitromodelsthataccuratelyrepresentthespectrumofdisease.Here,wedescribeamethodthatallowsfortheestab-lishmentofpatient-derived3Dorganoidlines.Asthisreportrep-resentsourinitialattempt,weanticipatethemethodcanbefurtheroptimizedtoimprovethesuccessratetogeneratethelargerepositoryoforganoidlinesrequiredtostudythishighlyheterogeneousdisease.Biopsyandcharacterizationofmeta-staticlesionsareincreasinglyincorporatedintotherapeuticclinicaltrialsoftargetedagentsinprostatecancer.Thisclinical


from patients with advanced prostate, bladder, or breast cancer as well as...Regardless of whether the peptidome is derived from the tissue/microenvironment...
[6], advanced melanoma [11], prostate cancer [...from healthy donors and from patients with chronic...In DC cultures of four healthy donors, Freezing ...
热门文档